Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease
Therapeutic efficacy of 225 Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy
Upfront Use of 177Lu-Labeled PSMA Radioligand Therapy and Treatment Response Assessment in Treatment-Naive Prostate Cancer
Therapeutic efcacy of 225Ac‑PSMA‑617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane‑based chemotherapy
Clinical Connect - Oncology - New Challenges, New Strategies
In‑House Preparation and Quality Control of Ac‑225 Prostate‑Specific Membrane Antigen‑617 for the Targeted Alpha Therapy of Castration‑Resistant Prostate Carcinoma
Exceptional Response to 177Lutetium Prostate-Specific Membrane Antigen in Prostate Cancer Harboring DNA Repair Defects
Vision Trial-Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer